Simple Summary
Prostate cancer is one of the most common cancers in men, but not all cases are life-threatening. Current blood tests, like the prostate-specific antigen test, often cannot tell the difference between aggressive and non-aggressive forms of the disease. This can lead to unnecessary treatment. Although magnetic resonance imaging can help, they are expensive and interpretations often vary significantly between radiologists. A promising new approach called metabolomics studies small molecules in blood and urine to identify patterns that distinguish serious prostate cancer from indolent forms. This review examines how these metabolic patterns, including pathways and metabolites consistently reported in more than one study, could assist doctors in better detecting aggressive cancer and avoiding overtreatment. Some of these patterns may even predict aggressive disease more accurately than existing tests. While more research is needed to strengthen these findings, this method could help develop noninvasive tests to support risk assessment before biopsy.
Abstract
Prostate cancer (PC) remains a major cause of cancer deaths in men. The serum biomarker prostate-specific antigen (PSA) lacks specificity in distinguishing clinically significant PC (sPC) from insignificant PC (isPC), leading to overdiagnosis and overtreatment. Although magnetic resonance imaging (MRI) improves detection, it is expensive, is time-consuming, and may involve inter-reader discrepancies. Recently, metabolomics, which has a high analytical sensitivity and broad molecular-feature coverage, has emerged as a promising tool to risk-stratify PC. This review examined studies of blood and urine metabolomics for sPC biomarker identification. Significant metabolite changes in sPC patients often involved fatty acid metabolism, sphingolipid metabolism, glycolysis, the citric acid cycle, purine/pyrimidine metabolism, and tyrosine/phenylalanine metabolism. Specifically, more than one study reported increased lactate and phenylalanine levels, along with decreased tyrosine, xanthine, and histidine levels, in sPC patients. Several metabolic panels outperformed serum PSA in predicting sPC, particularly when combined with clinical factors. Among these, two urine-based tests may have higher accuracy in predicting sPC than most current commercially available assays. However, direct comparison between studies may be inappropriate due to methodological heterogeneity, the variability in biospecimen types, inconsistent use of digital rectal examinations, and different sPC definitions and predictive endpoints. Most relevant studies were of small sample size or lacked external validation. Despite these challenges, metabolomics-based liquid biopsies show strong potential for improving sPC detection. Future research should focus on protocol standardization, MRI integration, absolute metabolite quantification, and validation in large and independent cohorts to enhance model credibility.